利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

55 条记录 (耗时 0.038 秒)

    Methods, Peptides, and Biosensors Useful for Detecting a Broad Spectrum of Bacteria
    2.
    发明申请
    Methods, Peptides, and Biosensors Useful for Detecting a Broad Spectrum of Bacteria 审中-公开
    用于检测广谱细菌的方法，肽和生物传感器

    公开(公告)号：US20150184220A1

    公开(公告)日：2015-07-02

    申请号：US14575898

    申请日：2014-12-18

    申请人： Woundchek Laboratories (US), Inc.

    发明人： Shite Sebastian ,  Gerard J. Colpas ,  Diane L. Ellis-Busby ,  Jennifer M. Harvard ,  Mitchell C. Sanders

    IPC分类号： C12Q1/37

    CPC分类号： C12Q1/37 ,  C07K7/08 ,  C07K14/001 ,  C12Q1/04 ,  G01N33/543 ,  G01N33/56911 ,  G01N2333/8121

    摘要： Described herein are methods of detecting a wound infection and for detecting the presence or absence of bacteria, for example, wound bacteria in a sample, by contacting a sample with a peptide substrate derived from the modification of the reactive site loop (RSL) domain of the α1-proteinase inhibitor. In the current invention, we have demonstrated that these peptide substrates without the alpha 1 protein can be efficiently used as peptide substrates. The modification or the absence of modification of this peptide substrate by the enzyme produced and/or secreted by the bacteria, can serve as an indicator for the presence or absence of the bacteria in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.

    摘要翻译： 本文描述的是检测伤口感染和检测样品中存在或不存在细菌，例如伤口细菌的方法，通过使样品与衍生自反应性位点环（RSL）结构域的修饰的肽底物接触 α1蛋白酶抑制剂。 在本发明中，我们已经证明，这些不含α1蛋白的肽底物可以有效地用作肽底物。 通过由细菌产生和/或分泌的酶修饰或不修饰该肽底物，可以作为样品中细菌存在或不存在的指标。 本发明还具有用于检测样品中细菌存在或不存在的生物传感器。

    Protein C inhibitor as a biomarker for prostate cancer
    4.
    发明授权
    Protein C inhibitor as a biomarker for prostate cancer 失效
    蛋白C抑制剂作为前列腺癌的生物标志物

    公开(公告)号：US08440409B2

    公开(公告)日：2013-05-14

    申请号：US11992000

    申请日：2006-09-19

    申请人： Zhen Zhang ,  Daniel W. Chan ,  Carolyn N. Rosenzwelg

    发明人： Zhen Zhang ,  Daniel W. Chan ,  Carolyn N. Rosenzwelg

    IPC分类号： G01N33/53 ,  G01N33/574

    CPC分类号： G01N33/57434 ,  G01N2333/8121

    摘要： The present invention provides a protein-based biomarker, Protein C Inhibitor (PCI) that is useful in qualifying prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as prostate cancer or non-prostate cancer. The biomarker can be detected by SELDI mass spectrometry.

    摘要翻译： 本发明提供了一种蛋白质生物标志物蛋白C抑制剂（PCI），其可用于鉴定患者中的前列腺癌状态。 特别地，本发明的生物标志物可用于将受试者样品分类为前列腺癌或非前列腺癌。 可通过SELDI质谱法检测生物标志物。

    Protein aggregation regulators
    7.
    发明授权
    Protein aggregation regulators 有权
    蛋白质聚集调节剂

    公开(公告)号：US07803559B1

    公开(公告)日：2010-09-28

    申请号：US10915203

    申请日：2004-08-09

    申请人： Marc I Diamond ,  Sonia K Pollitt

    发明人： Marc I Diamond ,  Sonia K Pollitt

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6896 ,  G01N2333/4709 ,  G01N2333/723 ,  G01N2333/76 ,  G01N2333/8121 ,  G01N2800/2821

    摘要： Disclosed herein is a high-throughput assay to measure intracellular polyglutamine protein aggregation using fluorescence resonance energy transfer (FRET). Three libraries of over 3000 biologically active small molecules were screened for inhibitory activity, and a lead compound was characterized in detail. Y-27632, an inhibitor of the Rho-associated kinase p160ROCK, diminished polyglutamine protein aggregation at micromolar concentrations, and reduced neurodegeneration in a Drosophila model of polyglutamine disease.

    摘要翻译： 本文公开了使用荧光共振能量转移（FRET）测量细胞内多谷氨酰胺蛋白聚集的高通量测定。 筛选出3000多种生物活性小分子的三个文库，进行抑制活性，并对铅化合物进行了详细的表征。 Y-27632是Rho相关激酶p160ROCK的抑制剂，在微摩尔浓度下减少聚谷氨酰胺蛋白聚集，并减少多聚谷氨酰胺病果蝇模型中的神经变性。

    COAGULATION AND FIBRINOLYSIS ASSAYS
    10.
    发明公开
    COAGULATION AND FIBRINOLYSIS ASSAYS 审中-公开

    公开(公告)号：US20240360492A1

    公开(公告)日：2024-10-31

    申请号：US18657130

    申请日：2024-05-07

    申请人： Massachusetts Institute of Technology ,  University of Colorado

    发明人： Michael B. Yaffe ,  Chris Barrett ,  Ernest Moore ,  Hunter Moore

    IPC分类号： C12Q1/56 ,  G01N33/49 ,  G01N33/86

    CPC分类号： C12Q1/56 ,  G01N33/4905 ,  G01N33/86 ,  C12Q2565/629 ,  G01N2333/8121 ,  G01N2333/968

    摘要： Coagulation and fibrinolysis assays and related compositions, systems, methods, and kits are provided. In some embodiments, a coagulation and fibrinolysis assay may utilize one or more biological molecules. For instance, the assay may comprise combining a blood or blood-derived patient sample with the biological molecule(s) and measuring one or more properties of the sample associated with coagulation and/or fibrinolysis. The biological molecules may serve to shorten the assay duration and/or enhance the sensitivity of the assay relative to certain conventional assays. In certain embodiments, the biological molecules may allow pathological coagulation and/or fibrinolysis phenotypes to be elucidated. The coagulation and fibrinolysis assays described herein may be used for a wide variety of clinical and/or laboratory applications, including the diagnosis of certain coagulation and/or fibrinolysis disorders, such as trauma-induced coagulopathy and hyperfibrinolysis.